12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Company News  |  Other News

Cardio3 BioSciences cardiovascular, gene/cell therapy news

Cardio3 received €3.1 million ($4 million) from the Walloon Region and the EU's seventh Framework Program (FP7). Cardio3 received the FP7 funding as part of a €5.9 million ($7.5...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >